Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma
AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang data...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Xiao-Lan Zhao [verfasserIn] Hong-Yu Zhu [verfasserIn] Yan-Ni Dai [verfasserIn] Xiao-Li Yang [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Guoji Yanke Zazhi - Press of International Journal of Ophthalmology (IJO PRESS), 2017, 23(2023), 4, Seite 624-629 |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2023 ; number:4 ; pages:624-629 |
| Links: |
|---|
| DOI / URN: |
10.3980/j.issn.1672-5123.2023.4.18 |
|---|
| Katalog-ID: |
DOAJ088741346 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ088741346 | ||
| 003 | DE-627 | ||
| 005 | 20230410122414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230410s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3980/j.issn.1672-5123.2023.4.18 |2 doi | |
| 035 | |a (DE-627)DOAJ088741346 | ||
| 035 | |a (DE-599)DOAJ5aee9f33cade475881428bb3886c713c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RE1-994 | |
| 100 | 0 | |a Xiao-Lan Zhao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. | ||
| 650 | 4 | |a ranibizumab | |
| 650 | 4 | |a compound trabeculectomy | |
| 650 | 4 | |a panretinal photocoagulation | |
| 650 | 4 | |a postoperative intraocular pressure | |
| 650 | 4 | |a best corrected visual acuity | |
| 650 | 4 | |a complications | |
| 653 | 0 | |a Ophthalmology | |
| 700 | 0 | |a Hong-Yu Zhu |e verfasserin |4 aut | |
| 700 | 0 | |a Yan-Ni Dai |e verfasserin |4 aut | |
| 700 | 0 | |a Xiao-Li Yang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Guoji Yanke Zazhi |d Press of International Journal of Ophthalmology (IJO PRESS), 2017 |g 23(2023), 4, Seite 624-629 |w (DE-627)1680946854 |x 16725123 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:4 |g pages:624-629 |
| 856 | 4 | 0 | |u https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5aee9f33cade475881428bb3886c713c |z kostenfrei |
| 856 | 4 | 0 | |u http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1672-5123 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_2817 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 4 |h 624-629 | ||
| author_variant |
x l z xlz h y z hyz y n d ynd x l y xly |
|---|---|
| matchkey_str |
article:16725123:2023----::eanlssfhefccoitairarnbzmbobndihopudrbclcoynpneiapoooglt |
| hierarchy_sort_str |
2023 |
| callnumber-subject-code |
RE |
| publishDate |
2023 |
| allfields |
10.3980/j.issn.1672-5123.2023.4.18 doi (DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c DE-627 ger DE-627 rakwb eng RE1-994 Xiao-Lan Zhao verfasserin aut Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology Hong-Yu Zhu verfasserin aut Yan-Ni Dai verfasserin aut Xiao-Li Yang verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 23(2023), 4, Seite 624-629 (DE-627)1680946854 16725123 nnns volume:23 year:2023 number:4 pages:624-629 https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 kostenfrei https://doaj.org/article/5aee9f33cade475881428bb3886c713c kostenfrei http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 23 2023 4 624-629 |
| spelling |
10.3980/j.issn.1672-5123.2023.4.18 doi (DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c DE-627 ger DE-627 rakwb eng RE1-994 Xiao-Lan Zhao verfasserin aut Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology Hong-Yu Zhu verfasserin aut Yan-Ni Dai verfasserin aut Xiao-Li Yang verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 23(2023), 4, Seite 624-629 (DE-627)1680946854 16725123 nnns volume:23 year:2023 number:4 pages:624-629 https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 kostenfrei https://doaj.org/article/5aee9f33cade475881428bb3886c713c kostenfrei http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 23 2023 4 624-629 |
| allfields_unstemmed |
10.3980/j.issn.1672-5123.2023.4.18 doi (DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c DE-627 ger DE-627 rakwb eng RE1-994 Xiao-Lan Zhao verfasserin aut Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology Hong-Yu Zhu verfasserin aut Yan-Ni Dai verfasserin aut Xiao-Li Yang verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 23(2023), 4, Seite 624-629 (DE-627)1680946854 16725123 nnns volume:23 year:2023 number:4 pages:624-629 https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 kostenfrei https://doaj.org/article/5aee9f33cade475881428bb3886c713c kostenfrei http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 23 2023 4 624-629 |
| allfieldsGer |
10.3980/j.issn.1672-5123.2023.4.18 doi (DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c DE-627 ger DE-627 rakwb eng RE1-994 Xiao-Lan Zhao verfasserin aut Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology Hong-Yu Zhu verfasserin aut Yan-Ni Dai verfasserin aut Xiao-Li Yang verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 23(2023), 4, Seite 624-629 (DE-627)1680946854 16725123 nnns volume:23 year:2023 number:4 pages:624-629 https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 kostenfrei https://doaj.org/article/5aee9f33cade475881428bb3886c713c kostenfrei http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 23 2023 4 624-629 |
| allfieldsSound |
10.3980/j.issn.1672-5123.2023.4.18 doi (DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c DE-627 ger DE-627 rakwb eng RE1-994 Xiao-Lan Zhao verfasserin aut Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology Hong-Yu Zhu verfasserin aut Yan-Ni Dai verfasserin aut Xiao-Li Yang verfasserin aut In Guoji Yanke Zazhi Press of International Journal of Ophthalmology (IJO PRESS), 2017 23(2023), 4, Seite 624-629 (DE-627)1680946854 16725123 nnns volume:23 year:2023 number:4 pages:624-629 https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 kostenfrei https://doaj.org/article/5aee9f33cade475881428bb3886c713c kostenfrei http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf kostenfrei https://doaj.org/toc/1672-5123 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 AR 23 2023 4 624-629 |
| language |
English |
| source |
In Guoji Yanke Zazhi 23(2023), 4, Seite 624-629 volume:23 year:2023 number:4 pages:624-629 |
| sourceStr |
In Guoji Yanke Zazhi 23(2023), 4, Seite 624-629 volume:23 year:2023 number:4 pages:624-629 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications Ophthalmology |
| isfreeaccess_bool |
true |
| container_title |
Guoji Yanke Zazhi |
| authorswithroles_txt_mv |
Xiao-Lan Zhao @@aut@@ Hong-Yu Zhu @@aut@@ Yan-Ni Dai @@aut@@ Xiao-Li Yang @@aut@@ |
| publishDateDaySort_date |
2023-01-01T00:00:00Z |
| hierarchy_top_id |
1680946854 |
| id |
DOAJ088741346 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ088741346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410122414.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3980/j.issn.1672-5123.2023.4.18</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088741346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5aee9f33cade475881428bb3886c713c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiao-Lan Zhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ranibizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">compound trabeculectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">panretinal photocoagulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">postoperative intraocular pressure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">best corrected visual acuity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complications</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hong-Yu Zhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yan-Ni Dai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiao-Li Yang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Guoji Yanke Zazhi</subfield><subfield code="d">Press of International Journal of Ophthalmology (IJO PRESS), 2017</subfield><subfield code="g">23(2023), 4, Seite 624-629</subfield><subfield code="w">(DE-627)1680946854</subfield><subfield code="x">16725123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:624-629</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3980/j.issn.1672-5123.2023.4.18</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5aee9f33cade475881428bb3886c713c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="h">624-629</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Xiao-Lan Zhao |
| spellingShingle |
Xiao-Lan Zhao misc RE1-994 misc ranibizumab misc compound trabeculectomy misc panretinal photocoagulation misc postoperative intraocular pressure misc best corrected visual acuity misc complications misc Ophthalmology Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| authorStr |
Xiao-Lan Zhao |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1680946854 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RE1-994 |
| illustrated |
Not Illustrated |
| issn |
16725123 |
| topic_title |
RE1-994 Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma ranibizumab compound trabeculectomy panretinal photocoagulation postoperative intraocular pressure best corrected visual acuity complications |
| topic |
misc RE1-994 misc ranibizumab misc compound trabeculectomy misc panretinal photocoagulation misc postoperative intraocular pressure misc best corrected visual acuity misc complications misc Ophthalmology |
| topic_unstemmed |
misc RE1-994 misc ranibizumab misc compound trabeculectomy misc panretinal photocoagulation misc postoperative intraocular pressure misc best corrected visual acuity misc complications misc Ophthalmology |
| topic_browse |
misc RE1-994 misc ranibizumab misc compound trabeculectomy misc panretinal photocoagulation misc postoperative intraocular pressure misc best corrected visual acuity misc complications misc Ophthalmology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Guoji Yanke Zazhi |
| hierarchy_parent_id |
1680946854 |
| hierarchy_top_title |
Guoji Yanke Zazhi |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1680946854 |
| title |
Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| ctrlnum |
(DE-627)DOAJ088741346 (DE-599)DOAJ5aee9f33cade475881428bb3886c713c |
| title_full |
Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| author_sort |
Xiao-Lan Zhao |
| journal |
Guoji Yanke Zazhi |
| journalStr |
Guoji Yanke Zazhi |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
624 |
| author_browse |
Xiao-Lan Zhao Hong-Yu Zhu Yan-Ni Dai Xiao-Li Yang |
| container_volume |
23 |
| class |
RE1-994 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Xiao-Lan Zhao |
| doi_str_mv |
10.3980/j.issn.1672-5123.2023.4.18 |
| author2-role |
verfasserin |
| title_sort |
meta-analysis of the efficacy of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| callnumber |
RE1-994 |
| title_auth |
Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| abstract |
AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. |
| abstractGer |
AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. |
| abstract_unstemmed |
AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_2817 |
| container_issue |
4 |
| title_short |
Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma |
| url |
https://doi.org/10.3980/j.issn.1672-5123.2023.4.18 https://doaj.org/article/5aee9f33cade475881428bb3886c713c http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf https://doaj.org/toc/1672-5123 |
| remote_bool |
true |
| author2 |
Hong-Yu Zhu Yan-Ni Dai Xiao-Li Yang |
| author2Str |
Hong-Yu Zhu Yan-Ni Dai Xiao-Li Yang |
| ppnlink |
1680946854 |
| callnumber-subject |
RE - Ophthalmology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3980/j.issn.1672-5123.2023.4.18 |
| callnumber-a |
RE1-994 |
| up_date |
2024-07-03T19:17:59.363Z |
| _version_ |
1803586664517337088 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ088741346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410122414.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230410s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3980/j.issn.1672-5123.2023.4.18</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ088741346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5aee9f33cade475881428bb3886c713c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RE1-994</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiao-Lan Zhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Meta-analysis of the efficacy of intravitreal Ranibizumab combined with compound trabeculectomy and panretinal photocoagulation in the treatment of neovascular glaucoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">AIM:To systematically evaluate the efficacy and safety of intravitreal ranibizumab combined with compound trabeculectomy and panretinal photocoagulation(PRP)compared with compound trabeculectomy combined with PRP in the treatment of neovascular glaucoma(NVG).METHODS: Databases including Wanfang database, China National Knowledge Infrastructure(CNKI), PubMed, EMbase, China Biomedical Document Service System(CBM), Clinicalkey, and Cochrane Library were retrieved. Literatures about intravitreal ranibizumab combined with compound trabeculectomy and PRP in the treatment of NVG in the experimental group and compound trabeculectomy and PRP in the treatment of NVG in the control group from creation of database to July 20, 2022 were searched. At the same time, relevant reference were consulted. The best corrected visual acuity, intraocular pressure, occurrence of complications and the success rate of the surgery were systematically evaluated.RESULTS: A total of 8 clinical studies were included, with 864 patients(864 eyes)with NVG. Meta-analysis showed that the intraocular pressure of patients in the experimental group was lower than that in the control group at 1wk, 1 and 3mo after surgery(1wk: MD=-4.00, 95%CI: -4.62～-3.38, P<0.05; 1mo: MD=-4.11, 95%CI: -4.66～-3.56, P<0.05; 3mo: MD=-4.58, 95%CI: -5.61～-3.55, P<0.05). The best corrected visual acuity of the experimental group was better than that of the control group at 1mo after surgery(MD=0.17, 95%CI: 0.11～0.23, P<0.05), but there was no significant difference at 1wk after surgery(MD=0.08, 95%CI: -0.13～0.29, P=0.47). The patients in the experimental group had fewer complications(OR=0.30, 95%CI: 0.18～0.52, P<0.05)and higher surgical success rate(OR=5.15, 95%CI: 2.78～9.53, P<0.05).CONCLUSION:With decreased intraocular pressure, improved visual acuity and surgical success rate, intravitreal ranibizumab combined with compound trabeculectomy and PRP was better than the compound trabeculectomy and PRP in the treatment of NVG.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ranibizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">compound trabeculectomy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">panretinal photocoagulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">postoperative intraocular pressure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">best corrected visual acuity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">complications</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Ophthalmology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hong-Yu Zhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yan-Ni Dai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xiao-Li Yang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Guoji Yanke Zazhi</subfield><subfield code="d">Press of International Journal of Ophthalmology (IJO PRESS), 2017</subfield><subfield code="g">23(2023), 4, Seite 624-629</subfield><subfield code="w">(DE-627)1680946854</subfield><subfield code="x">16725123</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:624-629</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3980/j.issn.1672-5123.2023.4.18</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5aee9f33cade475881428bb3886c713c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://ies.ijo.cn/cn_publish/2023/4/202304018.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1672-5123</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2023</subfield><subfield code="e">4</subfield><subfield code="h">624-629</subfield></datafield></record></collection>
|
| score |
7.3999224 |